Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Aptevo Therapeutics announced a presentation at the SITC 2026 Annual Meeting highlighting its CD40-directed multispecific cancer immunotherapy platform. Results have not been presented yet; the data are scheduled for November 4-8, 2026, with slides to be posted afterward. The work targets solid tumors by concentrating
Aptevo plans to present its multispecific CD40-directed platform at SITC 2026, emphasizing tumor-directed activation of innate and adaptive immunity.
Aptevo will present its multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on Nov. 4-8, 2026. The meeting is scheduled for the Phoenix Convention Center in Phoenix, Arizona. The presentation will cover tumor-directed CD40-activating multispecific molecules aimed at boosting ant